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Background
Our laboratory has discovered a 53-immune gene panel
predictive of survival in patients with stage II-III mela-
noma [1]. Validation is planned using tissues from a
multi-institutional cooperative group study. We tested
the 53-immune gene panel using publicly available data
for melanoma from The Cancer Genome Atlas (TCGA).
Methods
TCGA dataset for melanoma (n=407) was screened to
determine two extreme groups of patients – alive at least
4 years (n=67) and dead within 2 years from diagnosis
(n=59). Genome wide differential expression analysis was
performed between the two groups to study our prognos-
tic signature. We used gene set enrichment analysis
(GSEA) to evaluate the activation status of the 53 gene
panel as well as multiple immune lineage specific gene
sets[2]. We used PAM clustering algorithm to define two
groups based on the expression data of the 53 genes and
performed survival analysis on the unsupervised patient
clusters.
Results
Prognostic relevance of the 53 gene panel was tested
using supervised and unsupervised approaches. First, the
prognostic signature shows striking GSEA results
(p=2.24e-5) with activation of 51 of the 53 immune
genes in good prognosis patients, indicated by a right
shift in the enrichment score (Figure 1). GSEA of
immune lineage specific gene sets2 is shown in Figure 2.
Using an unsupervised approach we studied the 53 gene
panel across the whole population of melanoma cases
with clinical and expression data reported in the TCGA
(n=336). The generated heat map shows two distinct
clusters of expression (Figure 3). A Kaplan Meier curve
shows overall survival at 10 years in Cluster 1: 31.4 %
and Cluster 2: 45.6%, (p =0.00261).
Conclusions
Using publically available data from TCGA we tested
the 53-immune gene panel using supervised and unsu-
pervised approaches, showing that 51 of the 53 genes
are predictive of survival. This shows that the immune
genes may be operative in different stages of melanoma.
We propose using this panel to evaluate the effect of
immunotherapy across melanoma cohorts, and have
begun this analysis. We will also be evaluating the use
of the 53 immune genes and the specific immune gene
subsets on other cancer populations.
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